Akinola Ojeleye, MD
Family Medicine · Ottawa, KSNPI 1851327118
Payments from drug & device makers
Across 194 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$596
- Novo Nordisk$417
- AstraZeneca$209
- Amgen$141
- Pfizer$133
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$130
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $596 |
| Novo Nordisk | 26 | $417 |
| AstraZeneca(2 entities) | 15 | $209 |
| Amgen | 10 | $141 |
| Pfizer | 10 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Johnson & Johnson | 9 | $125 |
| Sunovion Pharmaceuticals Inc. | 10 | $110 |
| Merck | 6 | $95 |
| Lilly USA, LLC | 6 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $87 |
| Abbott | 3 | $71 |
| Boehringer Ingelheim | 4 | $70 |
| GSK | 4 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| GRT US Holding, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $34 |
| Biogen | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Bayer | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Saluda Medical Americas, Inc. | 1 | $19 |
| MML US, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Novartis | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Sanofi | 1 | $11 |
| Endogastric Solutions, Inc | 2 | $8 |
How this compares
$2,954 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $67,183 |
| EliquisApixaban | 64 | $39,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $25,004 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,373 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $9,305 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,604 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 207 | $4,221 |
| MyrbetriqMirabegron | 18 | $3,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $3,705 |
| Atorvastatin Calcium | 364 | $3,431 |
| Levemir FlexpenInsulin Detemir | 24 | $3,355 |
| Tamsulosin Hcl | 168 | $3,354 |
| Gabapentin | 257 | $3,030 |
| Novolog FlexpenInsulin Aspart | 21 | $2,985 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $417 | $67,18354 claims |
| PfizerEliquis | $133 | $39,01764 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $54 | $30,60952 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $3,80218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $2,76512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Ottawa
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.